Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
10x GenomicsTXG +14.44%61 Debt-to-Equity is 0.10 as of Jun. 2026, which is 9% below its 10-year median of 0.11. GuruFocus rates TXG with a GF Score™ of 61/100 and a GF Value™ of $18.78 (Significantly Overvalued). The stock has 8 warning signs investors should review. Among 557 Healthcare Providers & Services companies, 10x Genomics ranks better than 78.64% on this metric.
A high debt to equity ratio generally means that a company has been aggressive in financing its growth with debt. This can result in volatile earnings as a result of the additional interest expense.
The historical rank and industry rank for 10x Genomics's Debt-to-Equity or its related term are showing as below:
TXG'
s Debt-to-Equity Range Over the Past 10 Years
Min: -0.14 Med: 0.11 Max: 1.94
Current: 0.1
During the past 9 years, the highest Debt-to-Equity Ratio of 10x Genomics was 1.94. The lowest was -0.14. And the median was 0.11.
TXG's Debt-to-Equity is ranked better than 78.64% of 557
companies
in the Healthcare Providers & Services industry
Industry Median: 0.42
vs TXG: 0.10
Because a company can increase its ROE % by having more financial leverage, it is important to watch the leverage ratio when investing in high ROE % companies.
10x Genomics Debt-to-Equity Related Terms
10x Genomics Debt-to-Equity Historical Data
* Premium members only.
The historical data trend for 10x Genomics's Debt-to-Equity can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
For the Health Information Services subindustry, 10x Genomics's Debt-to-Equity, along with its competitors' market caps and Debt-to-Equity data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
10x Genomics Debt-to-Equity vs Healthcare Providers & Services Industry
For the Healthcare Providers & Services industry and Healthcare sector, 10x Genomics's Debt-to-Equity distribution charts can be found below:
* The bar in red indicates where 10x Genomics's Debt-to-Equity falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
10x Genomics (TXG) has a Debt-to-Equity of 0.10 as of Jun. 2026. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 10x Genomics and its competitors. This is near median its historical median of 0.11. According to the industry distribution chart, 10x Genomics ranks #119 out of 557 companies in the Healthcare Providers & Services industry, placing it in the top 21.4%.
Is 10x Genomics' Debt-to-Equity too high?
10x Genomics' current Debt-to-Equity of 0.10 is near median its 10-year median of 0.11. The Healthcare Providers & Services industry median Debt-to-Equity is 0.42. 10x Genomics' value of 0.10 is 76.2% below this industry median. Based on the distribution chart, 10x Genomics ranks #119 out of 557 companies in the Healthcare Providers & Services industry, which is in the top quartile — a strong position relative to peers. Overall, 10x Genomics has a GF Score™ of 61/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does 10x Genomics' Debt-to-Equity compare to HNGE and WAY?
According to the Healthcare Providers & Services industry distribution chart, 10x Genomics ranks #119 out of 557 companies for Debt-to-Equity. This places 10x Genomics in the top 21% of its industry — outperforming the majority of peers. The industry median Debt-to-Equity is 0.42. 10x Genomics' value of 0.10 is 76.2% below this benchmark. While the company's 10-year median is 0.11 vs. the industry median of 0.42, 10x Genomics has consistently been below the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Debt-to-Equity for a Healthcare Providers & Services company?
The median Debt-to-Equity among Healthcare Providers & Services companies is 0.42, based on 557 companies in the industry. Companies in the top quartile (top 25%) have a Debt-to-Equity significantly above this median, while those in the bottom quartile fall well below. However, Debt-to-Equity should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. 10x Genomics's current Debt-to-Equity of 0.10 is 76.2% below the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Debt-to-Equity mean?
A high Debt-to-Equity can signal that a stock is expensive relative to its fundamentals. Debt-to-Equity ratio represents the ratio of total debt to total company equity. View historical data on 10x Genomics and its competitors. For the Healthcare Providers & Services industry, the median Debt-to-Equity is 0.42 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. 10x Genomics's current Debt-to-Equity is 0.10, which is near median its own 10-year median of 0.11. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is 10x Genomics stock overvalued right now?
Based on GuruFocus' analysis, 10x Genomics (TXG) is currently considered Significantly Overvalued. The stock's GF Value™ is $18.78, compared to a current price of $59.68 — trading 217.8% above its estimated fair value. The current Debt-to-Equity is 0.10, which is near median its 10-year median of 0.11 and 76.2% below the Healthcare Providers & Services industry median of 0.42. 10x Genomics' overall GF Score™ is 61/100 with 8 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Debt-to-Equity calculated?
Debt-to-Equity is calculated from a company's financial statements. For 10x Genomics (TXG), the current Debt-to-Equity is 0.10 as of Jun. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is 10x Genomics (TXG) Overvalued in 2026?
Based on GuruFocus' analysis, 10x Genomics stock appears to be overvalued.
The current stock price of $59.68 is trading 217.8% above its estimated GF Value™ of $18.78.
GuruFocus considers 10x Genomics to be Significantly Overvalued.
Key valuation signals for TXG:
Debt-to-Equity: 0.10 (near median its 10-year median of 0.11)
GF Value™: $18.78 vs. price of $59.68 (217.8% above fair value)
Industry Position: 76.2% below the Healthcare Providers & Services median (#119 of 557)
No single metric tells the full story. See the TXG stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
10x Genomics Inc is a life science technology company based in the United States. Its solutions include instruments, consumables, and software for analyzing biological systems. The company's integrated solutions include instruments, consumables, and software for analyzing biological systems at a resolution and scale that matches the complexity of biology. Its product offerings include a Chromium platform comprising microfluidic chips and related consumables, Chromium X series, Visium and Xenium platforms, and others, which are predominantly used for the study of biological components. Geographically, the company derives operates from the United States and the rest from Americas (excluding the United States), Europe, Middle East and Africa, China, and Asia-Pacific (excluding China).
61GF Score
Get the complete analysis for TXG
Debt-to-Equity is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
TXG has been successfully added to your 
